Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX 1204 in moderate atopic dermatitis
NCT03824405Phase 2Completed
- Sponsor
- Botanix Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing BTX 1204 with Vehicle (2 arms). Primary endpoint: Investigator's Global Assessment at Day 85. Started Feb 2019; status: completed.
02
Drugs
BTX 1204
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03824405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824405.